Shanghai Blue鹊 Pharmaceutical

Blue Magpie Biopharmaceutical is a clinical-stage Chinese biotechnology company focused on the development of mRNA-based therapeutics and vaccines. Established in 2019, the company has built a comprehensive, vertically integrated mRNA platform encompassing sequence design, chemical synthesis of raw materials, and proprietary lipid nanoparticle (LNP) delivery systems. Its lead candidate is a variant-specific mRNA vaccine for COVID-19, which has progressed into mid-stage clinical trials. Beyond infectious diseases, Blue Magpie is expanding its pipeline into oncology and protein replacement therapies for rare diseases, leveraging its high-throughput discovery and manufacturing capabilities.